The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression.

Aged Alzheimer Disease / complications Amyloid beta-Peptides / metabolism Apolipoprotein E4 / genetics Cognitive Dysfunction / genetics Depressive Disorder, Major / complications Female Humans Male Middle Aged
Amyloid apolipoprotein E cognitive impairment late life depression

Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2021
Historique:
pubmed: 9 3 2021
medline: 15 9 2021
entrez: 8 3 2021
Statut: ppublish

Résumé

Cognitive impairment (CI) is a key feature of late life depression (LLD), but the contribution of underlying neurodegenerative pathology remains unclear. To evaluate cognitive dysfunction in LLD relative to a sample of nondepressed (ND) older adults with matched levels of memory impairment and amyloid-β (Aβ) burden. Participants included 120 LLD and 240 ND older adults matched on age, education, sex, Mini-Mental State Exam, mild cognitive impairment diagnosis, and PET Aβ burden. LLD showed higher rates of impairment relative to ND with 54.6% of the LLD sample demonstrating impairment in at least one cognitive domain compared to 42.9% of controls (H = 7.13, p = 0.008). LLD had poorer performance and higher rates of impairment on Rey Auditory Verbal Learning Test learning and memory compared to controls. In the overall sample, Aβ positivity was associated with worse performance on Logical Memory I (p = 0.044), Logical Memory II (p = 0.011), and Trail Making Test -B (p = 0.032), and APOEɛ4 genotype was associated with worse performance on Logical Memory I (p = 0.022); these relationships did not differ between LLD and ND. LLD showed higher rates of CI driven by focal deficits in verbal learning and memory. Alzheimer's disease (AD) biomarkers were associated with worse performance on timed set-shifting and story learning and memory, and these relationships were not impacted by depression status. These findings suggest that AD may account for a portion of previously reported multi-domain CI in LLD and highlight the potential for AD to confound studies of cognition in LLD.

Sections du résumé

BACKGROUND
Cognitive impairment (CI) is a key feature of late life depression (LLD), but the contribution of underlying neurodegenerative pathology remains unclear.
OBJECTIVE
To evaluate cognitive dysfunction in LLD relative to a sample of nondepressed (ND) older adults with matched levels of memory impairment and amyloid-β (Aβ) burden.
METHODS
Participants included 120 LLD and 240 ND older adults matched on age, education, sex, Mini-Mental State Exam, mild cognitive impairment diagnosis, and PET Aβ burden.
RESULTS
LLD showed higher rates of impairment relative to ND with 54.6% of the LLD sample demonstrating impairment in at least one cognitive domain compared to 42.9% of controls (H = 7.13, p = 0.008). LLD had poorer performance and higher rates of impairment on Rey Auditory Verbal Learning Test learning and memory compared to controls. In the overall sample, Aβ positivity was associated with worse performance on Logical Memory I (p = 0.044), Logical Memory II (p = 0.011), and Trail Making Test -B (p = 0.032), and APOEɛ4 genotype was associated with worse performance on Logical Memory I (p = 0.022); these relationships did not differ between LLD and ND.
CONCLUSION
LLD showed higher rates of CI driven by focal deficits in verbal learning and memory. Alzheimer's disease (AD) biomarkers were associated with worse performance on timed set-shifting and story learning and memory, and these relationships were not impacted by depression status. These findings suggest that AD may account for a portion of previously reported multi-domain CI in LLD and highlight the potential for AD to confound studies of cognition in LLD.

Identifiants

DOI: 10.3233/JAD-201089 PMID: 33682706 PMC: PMC8935860
pubmed: 33682706
pii: JAD201089
doi: 10.3233/JAD-201089
pmc: PMC8935860
mid: NIHMS1779254
doi:

Substances chimiques

Amyloid beta-Peptides 0
Apolipoprotein E4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

991-1002

Subventions

Organisme : NIBIB NIH HHS
ID : P41 EB015922
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH098062
Pays : United States
Organisme : NIA NIH HHS
ID : U24 AG021886
Pays : United States

Références

Arch Gen Psychiatry. 2011 Nov;68(11):1143-50
pubmed: 22065530
Am J Psychiatry. 2000 Dec;157(12):1949-54
pubmed: 11097959
Am J Psychiatry. 1996 Oct;153(10):1280-7
pubmed: 8831435
JAMA. 2004 Mar 3;291(9):1081-91
pubmed: 14996777
Ann Neurol. 2013 Dec;74(6):826-36
pubmed: 23536396
Psychopharmacol Bull. 1988;24(4):709-11
pubmed: 3249773
Alzheimers Dement. 2015 Jul;11(7):792-814
pubmed: 26194313
J Clin Exp Neuropsychol. 1987 Oct;9(5):479-97
pubmed: 2959682
J Gerontol A Biol Sci Med Sci. 2003 Mar;58(3):249-65
pubmed: 12634292
J Clin Exp Neuropsychol. 1999 Aug;21(4):572-82
pubmed: 10550815
Arch Gen Psychiatry. 2011 Jan;68(1):51-60
pubmed: 21199965
Alzheimers Dement. 2015 Jul;11(7):757-71
pubmed: 26194311
Nat Rev Neurol. 2011 May 03;7(6):323-31
pubmed: 21537355
BMC Psychiatry. 2014 May 07;14:130
pubmed: 24886463
Lancet Neurol. 2012 Aug;11(8):669-78
pubmed: 22749065
Arch Gen Psychiatry. 2004 Jun;61(6):587-95
pubmed: 15184238
Alzheimers Dement. 2018 Jul;14(7):913-924
pubmed: 29601787
Am J Geriatr Psychiatry. 2009 Apr;17(4):308-16
pubmed: 19307859
Int Psychogeriatr. 2009 Oct;21(5):879-88
pubmed: 19519984
Am J Geriatr Psychiatry. 2006 May;14(5):419-27
pubmed: 16670246
Am J Geriatr Psychiatry. 2011 Feb;19(2):176-84
pubmed: 20808129
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Am J Geriatr Psychiatry. 2001 Summer;9(3):269-74
pubmed: 11481135
Neurobiol Aging. 2010 Aug;31(8):1275-83
pubmed: 20472326
Arch Gen Psychiatry. 1997 Oct;54(10):915-22
pubmed: 9337771
EJNMMI Res. 2017 Dec;7(1):24
pubmed: 28324341
J Affect Disord. 2013 Sep 25;150(3):736-44
pubmed: 23870425
Neurology. 2010 Jan 19;74(3):201-9
pubmed: 20042704
Alzheimers Dement. 2014 Nov;10(6):861-8
pubmed: 25217293
J Int Neuropsychol Soc. 2014 May;20(5):461-7
pubmed: 24685173
JAMA Neurol. 2016 Jan;73(1):85-92
pubmed: 26595683
Psychol Med. 2010 Apr;40(4):591-602
pubmed: 19656429
Psychol Aging. 2004 Dec;19(4):592-600
pubmed: 15584785
Aging (Milano). 1999 Apr;11(2):90-5
pubmed: 10386168
Int Psychogeriatr. 2007 Feb;19(1):125-35
pubmed: 16834811
Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):261-8
pubmed: 18580591
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Am J Psychiatry. 1984 Nov;141(11):1356-64
pubmed: 6496779
Am J Geriatr Psychiatry. 2009 May;17(5):368-75
pubmed: 19390294
Lancet. 2005 Jun 4-10;365(9475):1961-70
pubmed: 15936426
Clin Neuropsychol. 2020 Apr;34(3):437-453
pubmed: 32037942
J Alzheimers Dis. 2014;42(1):275-89
pubmed: 24844687
Acta Psychiatr Scand. 2002 Jan;105(1):20-7
pubmed: 12086221
Am J Psychiatry. 2002 Jul;159(7):1119-26
pubmed: 12091189
Neuropsychology. 2019 Mar;33(3):406-416
pubmed: 30730162
J Alzheimers Dis. 2016 Mar 31;52(2):685-91
pubmed: 27031477
Int J Geriatr Psychiatry. 2007 Jun;22(6):563-7
pubmed: 17136705
Arch Gen Psychiatry. 2000 Mar;57(3):285-90
pubmed: 10711915
Biol Psychiatry. 2006 Jul 1;60(1):58-65
pubmed: 16414031

Auteurs

Emma Rhodes (E)

Mental Illness Research Education and Clinical Centers, Veterans Administration Medical Center, San Francisco, CA, USA.

Philip S Insel (PS)

Department of Psychiatry, University of California, San Francisco, CA, USA.
Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.

Meryl A Butters (MA)

Department of Psychiatry, Western Psychiatric Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Ruth Morin (R)

Mental Illness Research Education and Clinical Centers, Veterans Administration Medical Center, San Francisco, CA, USA.

David Bickford (D)

Department of Psychiatry, University of California, San Francisco, CA, USA.

Duygu Tosun (D)

Veterans Administration Medical Center, San Francisco, CA, USA.
Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.

Devon Gessert (D)

University of Southern California, Los Angeles, CA, USA.

Howie J Rosen (HJ)

Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.

Paul Aisen (P)

University of Southern California, Los Angeles, CA, USA.
Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA.

Rema Raman (R)

University of Southern California, Los Angeles, CA, USA.
Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA.

Susan Landau (S)

Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA.

Andrew Saykin (A)

Indiana University School of Medicine, Indianapolis, IN, USA.

Arthur Toga (A)

Laboratory of Neuro Imaging, Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Clifford R Jack (CR)

Department of Radiology, Mayo Clinic, Rochester, MN, USA.

Michael W Weiner (MW)

Department of Psychiatry, University of California, San Francisco, CA, USA.
Veterans Administration Medical Center, San Francisco, CA, USA.
Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.

Craig Nelson (C)

Department of Psychiatry, University of California, San Francisco, CA, USA.

Scott Mackin (S)

Department of Psychiatry, University of California, San Francisco, CA, USA.
Department of Psychiatry, Western Psychiatric Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › The Impact of Amyloid Burden and APOE on Rates...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › The Impact of Amyloid Burden and APOE on Rates...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › The Impact of Amyloid Burden and APOE on Rates...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Apolipoprotéines › Apolipoprotéines E › Apolipoprotéine E4 › The Impact of Amyloid Burden and APOE on Rates...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › The Impact of Amyloid Burden and APOE on Rates...
questionsmedicales.fr › Troubles mentaux › Troubles de l'humeur › Trouble dépressif › Trouble dépressif majeur › The Impact of Amyloid Burden and APOE on Rates...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Impact of Amyloid Burden and APOE on Rates...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › The Impact of Amyloid Burden and APOE on Rates...